Table 2 Characteristics of 10 implementation trials in a clinical setting with an embedded economic evaluation
Study characteristic | Citation number(s) | Â Output |
|---|---|---|
Publication year, median (range) |  | 2013 (1990–2022) |
Country, n (%) | ||
 USA | (22, 27–29) | 4 (40%) |
 UK and Europe | (25, 26, 30) | 3 (30%) |
 Africa | (23, 24, 31) | 3 (30%) |
Health sector, n (%) | ||
 Primary | (22–28) | 7 (70%) |
 Secondary | (29) | 1 (10%) |
 Tertiary | (30, 31) | 2 (20%) |
Clinical setting, n (%) | ||
 Out-patient | (22–29) | 8 (80%) |
 In-patient | (30, 31) | 2 (20%) |
Study population, n (%) | ||
 All patients | (23, 25, 26) | 3 (30%) |
 Older adults (40 + years) | (27–29) | 3 (30%) |
 Birthing people | (30) | 1 (10%) |
 Patients aged 15 + years | (24) | 1 (10%) |
 Children and adolescents | (22, 31) | 2 (20%) |
Implementation outcomes, n (%) | ||
 Quality improvement | (31) | 1 (10%) |
 Adoption | (26–30) | 5 (50%) |
 Penetration | (22–25) | 4 (40%) |